Article Figures & Data
Figures
- FIGURE 1.
Actual cell number as calculated from standard curve.
- FIGURE 2.
3H-FDG uptake per cell (A) and per well (B) in untreated and treated MCF-7 cells.
- FIGURE 3.
Comparison of glut-1 mRNA, HKII mRNA, 3H-FDG per cell, and MTT results in untreated MCF-7 cells.
- FIGURE 4.
Comparison of glut-1 mRNA, HKII mRNA, 3H-FDG per cell, and MTT results in DOX-treated MCF-7 cells.
- FIGURE 5.
Comparison of Glut-1 mRNA, HKII mRNA, 3H-FDG per cell, and MTT results in 5FU-treated MCF7 cells.
- FIGURE 6.
Results of regression analysis using real-time mRNA data and 3H-FDG uptake per cell: untreated vs. glut-1 (A), untreated vs. HKII (B), DOX vs. glut-1 (C), DOX vs. HKII (D), 5FU vs. glut-1 (E), and 5FU vs. HKII (F). y-Axis represents percentage of baseline expression of mRNA; x-axis represents percentage of baseline 3H-FDG uptake.
- FIGURE 7.
Western blot analysis of total protein extractions from untreated and DOX- and 5FU-treated MCF-7 cells. Comparable amounts of total protein are loaded in each lane, as shown by β-actin. HKII protein rises in untreated cells and falls in treated cells. Glut-1 protein levels change less than does mRNA. UNT = untreated.
Tables
Parameter Sequence Glut-1 Forward 5′-GCA ACG CCT GCT ACA TGG A-3′ Reverse 5′-GAT ACA CAT CCG CCC CTC AT-3′ Probe 5′-CGC CAC ATC GAC ATG GTG GAA GG-3′ HKII Forward 5′-CAT CGT CGT CGG CAT CCT-3′ Reverse 5′-CCT TGT TGC CCA TGA TGG A-3′ Probe 5′-ATC GCC CAG GTG TTC GGC CTG-3′ β-actin Forward 5′-TCA CCC ACA CTG TGC CCA TCT ACG A-3′ Reverse 5′-TCG GTG AGG ATC TTC ATG AGG TA-3′ Probe 5′-ATG CCC TCC CCC ATG CCA TCC-3′
Jump to section
Related Articles
Cited By...
- Comparison of EORTC Criteria and PERCIST for PET/CT Response Evaluation of Patients with Metastatic Colorectal Cancer Treated with Irinotecan and Cetuximab
- Interim FDG-PET in Hodgkin lymphoma: a compass for a safe navigation in clinical trials?
- From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
- PET/CT for Therapy Response Assessment in Lymphoma
- 18F-FDG PET/CT for Monitoring the Response of Lymphoma to Radioimmunotherapy
- Colorectal Tumor Cells Treated with 5-FU, Oxaliplatin, Irinotecan, and Cetuximab Exhibit Changes in 18F-FDG Incorporation Corresponding to Hexokinase Activity and Glucose Transport
- Integrating PET and PET/CT into the Risk-Adapted Therapy of Lymphoma